AstraZeneca began its research efforts on identifying and developing antibody therapies against Covid-19 infection. The company will use its in-house capabilities and form alliances to discover monoclonal antibodies that could detect, attach to, and neutralize the SARS-CoV-2.
Synthesized in a laboratory, monoclonal antibodies work similarly to natural antibodies. Internally, biopharmaceutical experts at AstraZeneca are leveraging its antibody discovery technology, which previously helped in identifying potential antibodies for influenza-A.
Among these partners, the Chinese Academy of Sciences and Vanderbilt University Medical Center in the US will provide genetic sequences for anti- SARS-CoV-2 antibodies identified by them.
AstraZeneca will conduct an in-silico and in-vitro evaluation of these antibodies. The antibodies discovered internally by the company will be tested preclinically through partnerships with the United States Army Medical Research Institute of Infectious Diseases and the University of Maryland School of Medicine.
Researchers at the company will analyze recovered Covid-19 patients, immunized humanized mice, and laboratory techniques for antibodies against the novel coronavirus. AstraZeneca expects to advance potential antibodies into clinical evaluation within three to five months.